Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …

Purpose: To investigate the potential use of accelerator mass spectrometry (AMS) in the
study of the clinical pharmacology of imatinib. Experimental Design: Six patients who were …

We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …

We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid
leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to …

The present study looked at the correlation between mean trough Imatinib plasma levels
and molecular response in 131 CML patients on imatinib. Patients receiving Glivec versus …

To explore the long-term efficacy of imatinib to chronic myeloid leukemia, a total of 46 late
chronic phase (CP) patients were assessed after achieving complete cytogenetic response …

To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or
molecular responses, we measured trough IM levels in patients with chronic myeloid …

Abstract Abstract 505 Background: Therapy with imatinib and other tyrosine kinase inhibitors
leads to complete cytogenetic response (CCyR) in 80-90% of patients in chronic phase (CP) …

The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …

Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …